Eximias' Thymitaq fails HCC Phase III

Eximias (Berwyn, Penn.) said Thymitaq nolatrexed missed the primary endpoint of survival in the Phase III ETHECC trial to treat unresectable hepatocellular carcinoma (HCC). Data from the international...